HC Wainwright Brokers Raise Earnings Estimates for MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Research analysts at HC Wainwright boosted their Q2 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research report issued on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.76) per share for the quarter, up from their previous forecast of ($0.78). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($2.93) EPS, Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($1.03) EPS and FY2026 earnings at ($3.68) EPS.

Several other research analysts have also recently weighed in on the stock. The Goldman Sachs Group lowered their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Royal Bank of Canada started coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $67.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $80.00 price target (up from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Finally, Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target on the stock in a research report on Monday, May 19th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $78.71.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock traded up $0.10 during trading hours on Thursday, hitting $39.06. The company had a trading volume of 228,946 shares, compared to its average volume of 350,821. The firm has a market cap of $2.50 billion, a PE ratio of -30.28 and a beta of 1.31. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.26. The firm has a 50-day moving average of $38.29 and a 200 day moving average of $44.01.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same quarter in the prior year, the firm earned ($0.22) earnings per share.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently added to or reduced their stakes in MLTX. Congress Asset Management Co. grew its position in MoonLake Immunotherapeutics by 9.5% during the fourth quarter. Congress Asset Management Co. now owns 72,993 shares of the company's stock worth $3,953,000 after buying an additional 6,352 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 47.3% in the 4th quarter. Rice Hall James & Associates LLC now owns 111,133 shares of the company's stock valued at $6,018,000 after purchasing an additional 35,664 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of MoonLake Immunotherapeutics by 3.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock valued at $460,000 after purchasing an additional 320 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of MoonLake Immunotherapeutics by 18.4% in the 4th quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock valued at $354,000 after purchasing an additional 1,013 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of MoonLake Immunotherapeutics by 5.8% in the 4th quarter. Sei Investments Co. now owns 22,025 shares of the company's stock valued at $1,193,000 after purchasing an additional 1,202 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.